NEW YORK, Oct. 7 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Therapeutic Monoclonal Antibodies: World Market 2010-2025
http://www.reportlinker.com/p0306322/Therapeutic-Monoclonal-Antibodies-World-Market-2010-2025.html
In 2009, the therapeutic monoclonal antibodies market generated total revenues of over $35bn worldwide. From 2010 onwards, this sector will benefit from new drugs and expanding indications for existing products, our latest study shows. New technologies will be an important driver of revenue growth. Intensive R&D activity is producing a strong R&D pipeline, filled with novel monoclonal antibodies, antibody fragments and antibody-drug conjugates. We expect significant opportunities for further commercial growth, as discussed in our latest report.
Therapeutic Monoclonal Antibodies: World Market 2010-2025 explains how this market will develop, and where the commercial opportunities will lie. There remain high revenues to be made in this sector from 2010 to 2025. Our report explains where, why and by whom. What will be the characteristics of drugs that will succeed Avastin and Remicade? Will they become the blockbusters of the future? What are the potential applications and prospects for antibody fragments? Which R&D pipeline agents have most commercial promise? Our report will show you the outlook for this dynamic sector, providing information that will benefit your work, saving you time and aiding your decision making.
Our report covers the following products in detail:
- Avastin
- Herceptin
- MabThera
- Erbitux
- Remicade
- Humira
- Tysabri
- Synagis
- Lucentis
- Xolair.
What monoclonal antibodies are likely to enter the market from 2010 onwards, and will they dominate? How will patent expiry and biosimilar products influence the market? Where will the main opportunities lie, and what are the drivers and restraints in this industry and market? Our report will provide you with the information that you need to understand current trends and future directions in the market for therapeutic monoclonal antibodies.
Comprehensive analysis of the industry and market for therapeutic mAbs
Therapeutic Monoclonal Antibodies: World Market 2010-2025 examines that sector through a comprehensive review of information sources. We harness primary and secondary research. This report provides sales forecasts, market share analyses, discussions of R&D pipeline developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are over 80 tables and figures included, as well as three interviews with experts. The result is a market- and industry-centred study, with detailed analyses and opinion to benefit your work.
Why you should buy Therapeutic Monoclonal Antibodies: World Market 2010-2025
Our report gives you the following benefits in particular:
- You will assess the current market for therapeutic monoclonal antibodies, as well as recent trends there
- You will review the overall market area from 2010 to 2025, including global sales forecasts
- You will receive forecasts for the main subgroups of the therapeutic mAbs market, showing you where opportunities for revenue growth will occur from 2010 onwards
- You will receive sales forecasts for the leading products in this market from 2010 to 2025, with discussions of market potential and competition
- You will receive sales forecasts for leading geographical markets from 2010 to 2025, with discussions and other supporting information
- You will analyse the drivers, restraints, competition and opportunities influencing the market for therapeutic monoclonal antibodies from 2010 onwards
- You will investigate under-met needs, with therapeutic requirements and commercial opportunities covered
- You will discover the most exciting R&D pipeline developments in the sector
- You will receive expert views on the sector, including full interview transcripts.
You can obtain this report today
Our new report is essential reading for everybody interested in the expanding market for therapeutic monoclonal antibodies. This report provides an analysis of the world market, giving a balanced view of technological and commercial prospects there. Do you want to know more about this important market and harness its opportunities? You can stay ahead by ordering our report today.
Table of Contents
1. Executive Summary
1.1 Monoclonal Antibody Market Review
1.2 Aims, Scope and Format of the Report
1.3 Research and Analysis Methods
2. Introduction to Monoclonal Antibodies
2.1 Antibodies
2.1.1 Function of Antibodies
2.1.2 Structure of Antibodies
2.2 Therapeutic Monoclonal Antibodies
2.2.1 Polyclonal and Monoclonal Antibodies
2.2.2 Murine Monoclonal Antibodies
2.2.3 Chimeric and Humanised Monoclonal Antibodies
2.2.4 Fully-Human Monoclonal Antibodies
2.2.5 Currently-Approved Monoclonal Antibody Therapies
3. World Therapeutic Monoclonal Antibodies Market, 2010-2025
3.1 Therapeutic Monoclonal Antibodies: Market Overview
3.1.1 The Therapeutic Monoclonal Antibody Market, 2009
3.1.2 Monoclonal Antibodies: Revenue Analysis by Therapeutic Area, 2009
3.1.3 Leading Therapeutic Monoclonal Antibodies, 2009
3.1.4 Monoclonal Antibodies: Revenue Analysis by Group, 2009
3.1.5 World Monoclonal Antibody Market: Overall Forecast, 2010-2015
3.1.6 World Monoclonal Antibody Market: Overall Forecast, 2015-2025
3.2 The Market for Anti-Cancer Monoclonal Antibodies
3.2.1 The Leading Anti-Cancer Monoclonal Antibodies, 2009
3.2.2 Anti-Cancer Monoclonal Antibodies: Revenue Analysis by Type, 2009
3.2.3 Anti-Cancer Monoclonal Antibodies: Revenue Analysis by Company, 2009
3.2.4 Anti-Cancer Monoclonal Antibodies Market, 2010-2015
3.2.5 Anti-Cancer Monoclonal Antibodies Market, 2015-2025
3.3 Avastin
3.3.1 Avastin: Cancer Blockbuster Set to Reach $10bn?
3.3.2 Avastin Revenue Analysis, 2009
3.3.3 Avastin 2010-2015: 'a Pipeline-in-One'
3.3.4 The Competitive Landscape for Avastin, 2010-2015
3.3.5 Avastin Market Forecast, 2010-2015
3.3.6 Outlook for Avastin: Sales Forecast, 2015-2025
3.4 Herceptin
3.4.1 Herceptin Successfully Targets HER2-Positive Patients
3.4.2 Herceptin Revenue Analysis, 2009
3.4.3 Herceptin Market Forecast, 2010-2015
3.4.4 Increased Competition for Herceptin, 2015-2025
3.5 MabThera/Rituxan
3.5.1 MabThera/Rituxan: The First Blockbuster Monoclonal Antibody
3.5.2 MabThera/Rituxan Revenue Analysis, 2009
3.5.3 MabThera/Rituxan Market Forecast, 2010-2015
3.5.4 MabThera/Rituxan Long-Term Prospects, 2015-2025
3.5.5 New Oncology Growth Areas for MabThera/Rituxan, 2010-2015
3.5.6 Intensifying Competition: MabThera/Rituxan in Cancer Treatment, 2015-2025
3.6 Erbitux
3.6.1 Erbitux' Oncology Indications
3.6.2 Erbitux Revenue Analysis, 2009
3.6.3 Opportunities in Head and Neck Cancer and New Indications for Erbitux
3.6.4 Erbitux Sales Forecast, 2010-2025
3.7 Other Monoclonal Antibodies for Treating Cancers
3.7.1 Vectibix
3.7.2 Campath/MabCampath
3.7.3 Zevalin
3.7.4 Bexxar
3.7.5 TheraCIM (Nimotuzumab)
3.7.6 Removab
3.8 The Autoimmune Disorder Monoclonal Antibodies Market
3.8.1 Leading Autoimmune Disorder Monoclonal Antibodies: Revenue Analysis, 2009
3.8.2 Autoimmune Disorder Monoclonal Antibodies: Revenue Analysis by Type, 2009
3.8.3 Remicade, Humira and Novel Antibodies Drive Autoimmune Monoclonal Market, 2010-2015
3.8.4 Autoimmune Disorder Monoclonal Antibodies Sales Forecast, 2015-2025
3.9 Remicade
3.9.1 Remicade: The Leading Monoclonal Antibody, 2009
3.9.2 Remicade Revenue Analysis, 2009
3.9.3 Remicade's Competitors
3.9.4 Imminent Increase in Competition for Remicade
3.9.5 Remicade Market Forecast, 2010-2015
3.9.6 Remicade Market Forecast, 2015-2025
3.10 Humira
3.10.1 Humira: First Fully-Human Monoclonal Antibody on the Market
3.10.2 Humira Revenue Analysis, 2009
3.10.3 Humira's Market Potential, 2010-2015
3.10.4 Humira Sales Forecast, 2015-2025
3.11 Tysabri
3.11.1 Tysabri - A Monoclonal Antibody for the Treatment of MS
3.11.2 Tysabri Revenue Analysis, 2009
3.11.3 Tysabri Sales Forecast, 2010-2025
3.11.4 Tysabri Will Face Competition from Oral MS Drugs
3.12 Xolair
3.12.1 Genentech's Asthma Monoclonal Antibody: Xolair
3.12.2 Xolair Revenue Analysis, 2009
3.12.3 Xolair Sales Forecast, 2010-2025
3.13 MabThera/Rituxan for Rheumatoid Arthritis
3.13.1 Competitors for MabThera/Rituxan in Autoimmune Disorders, 2010-2025
3.13.2 Prospects for Revenue Growth
3.14 Other Monoclonal Antibodies for Treating Autoimmune Disorders
3.14.1 Cimzia
3.14.2 Simponi
3.14.3 Soliris
3.14.4 Simulect
3.14.5 Actemra/RoActemra
3.14.6 Stelara
3.15 Other Monoclonal Antibodies (Non-Oncology/Autoimmune Disorders)
3.15.1 Other Leading Monoclonal Antibodies: Revenue Analysis, 2009
3.15.2 Other Monoclonal Antibodies: Sales Forecast, 2010-2025
3.16 Synagis
3.16.1 Synagis: Blockbuster Respiratory Disorder Treatment
3.16.2 Synagis Revenue Analysis, 2009
3.16.3 Synagis Market Forecast, 2010-2025
3.17 Lucentis
3.17.1 Lucentis: Antibody Fragment for Ophthalmology
3.17.2 Lucentis Revenue Analysis, 2009
3.17.3 Impact of Off-Label Avastin on Lucentis, 2010-2025
3.17.4 Lucentis Sales Forecast, 2010-2015
3.17.5 Lucentis Sales Forecast, 2015-2025
3.18 ReoPro
3.18.1 ReoPro: Cardiovascular Monoclonal Antibody Fragment
3.18.2 ReoPro Revenue Analysis, 2009
4. Leading National Markets for Monoclonal Antibody Therapies, 2010-2025
4.1 Regional Overview
4.1.1 Top Seven National Markets for Therapeutic Monoclonal Antibodies
4.2 The US Monoclonal Antibody Therapeutics Market
4.2.1 US Market in 2009
4.2.2 US Monoclonal Antibody Therapeutics Market, 2010-2025
4.3 The Japanese Monoclonal Antibody Therapeutics Market, 2010-2025
4.4 Leading European Monoclonal Antibody Therapeutics Markets, 2010-2025
4.5 Prospects for Therapeutic Monoclonal Sales in Emerging Markets, 2010-2025
5. The R&D Pipeline for Therapeutic Monoclonal Antibodies
5.1 Late-Stage Oncology Pipeline: Additional and Expanded Indications
5.1.1 Avastin
5.1.2 MabThera/Rituxan
5.1.3 Erbitux
5.1.4 Tysabri
5.2 Late-Stage Oncology Pipeline: Novel Entities
5.2.1 Farletuzumab (MORAb-003)
5.2.2 Figitumumab (CP-751871)
5.2.3 Galiximab
5.2.4 Ipilimumab
5.2.5 Ramucirumab (IMC 1121B)
5.2.6 Rencarex (WX-G250)
5.2.7 Zalutumumab (HuMax-EGFr)
5.2.8 Lumiliximab
5.2.9 Pertuzumab (R1273)
5.3 Late-Stage Autoimmune Disorder Pipeline: Additional and Expanded Indications
5.3.1 MabThera/Rituximab
5.3.2 Alemtuzumab for Multiple Sclerosis
5.4 Late-Stage Autoimmune Disorder Pipeline: New Entities
5.4.1 Benlysta (Belimumab)
5.4.2 Bapineuzumab (AAB-001)
5.4.3 Briakinumab (ABT-874)
5.4.4 Mycograb (Efungumab)
5.4.5 Ocrelizumab (R1594)
5.4.6 Otelixizumab (TRX4)
5.5 Other Monoclonal Antibodies Pipeline (Non-Oncology/Autoimmune Disorders)
5.5.1 Motavizumab
5.5.2 Lucentis
5.6 Early Stage Pipeline: Antibody Fragments
5.6.1 Development and Potential of Antibody Fragments
5.6.2 Ablynx' Nanobodies
5.6.3 Domantis' Domain Fragments
5.6.4 Genmab's UniBodies
5.6.5 ESBATech
5.6.6 Affimed's TandAbs and Flexibodies
5.6.7 Micromet's BiTE Antibody Platform
5.7 Early Stage Pipeline: Antibody-Drug Conjugates
5.7.1 The Future of Conjugated Antibodies
5.7.2 Seattle Therapeutics
5.7.3 ImmunoGen's TAP Technology
5.7.4 Neuradiab
6. Issues Affecting the Therapeutic Monoclonal Antibodies Industry and Market, 2010-2025
6.1 SWOT Analysis of the Therapeutic Monoclonal Antibodies Industry and Market
6.2 Commercial Strengths
6.2.1 Monoclonal Antibodies Have a Wide Range of Specific Targets
6.2.2 Chronic and Niche Diseases Generate High Revenues
6.2.3 Strong R&D Pipeline and Technological Advances, Including Manufacturing Improvements
6.2.4 Lower Risk of Adverse Events for Monoclonal Antibodies in Cancer Treatment
6.3 Commercial Weaknesses
6.3.1 Biosimilar Monoclonal Antibodies
6.3.2 Future Prospects for Biosimilar Monoclonal Antibodies
6.3.3 High Development Cost Limits Growth
6.3.4 Injections are the Main Mode of Administration
6.3.5 The Challenge of Immunogenicity Still Present
6.3.6 Competition is Fierce for Many Targets
6.3.7 Insufficient Efficacy of Anti-Cancer Monoclonal Antibodies as Monotherapy – a Concern
6.4 Commercial Opportunities
6.4.1 Increasing Cancer Prevalence – Expanding Treatment Populations
6.4.2 Autoimmune Disorder Prevalence and Under-Treatment
6.5 Commercial Threats
6.5.1 Reimbursement for Monoclonal Antibodies
6.5.2 High Profile Safety Cases Increase Regulatory Vigilance
6.5.3 Current Financial Limitations in Research and Development
7. Interviews with Experts on the Sector
7.1 Interview 1: Dr Janice M. Reichert
7.1.1 Major Challenges and Opportunities for Monoclonal Antibody Cancer Therapeutics
7.1.2 Side-Effects of Monoclonal Antibodies for Cancer
7.1.3 Future Developments and Pipelines
7.1.4 The Effect of Biosimilars
7.2 Interview 2: Dr David Blakey
7.2.1 The Future of Humanised and Fully-Human Antibodies
7.2.2 Therapeutic Antibody Fragments versus Full-Length Antibodies
7.2.3 Major Opportunities in Monoclonal Antibody Cancer Therapeutics
7.3 Interview 3: Dr Mark Cragg
7.3.1 How Do Monoclonal Antibodies Treat Cancer?
7.3.2 The Future of Different Monoclonal Antibody Types
7.3.3 Threats and Limitations
7.3.4 Opportunities
7.3.5 Will Side Effects Limit Growth?
7.3.6 Future Developments
8. Conclusions
8.1 Monoclonal Antibodies Account for Over 30% of Biologic Drug Revenues
8.2 Prospects for the Therapeutic Monoclonal Antibody Industry and Market
8.3 The Monoclonal Antibody R&D Pipeline
8.4 Recent High Growth Rates Set to Continue to 2015
8.5 Market Forecast from 2015 Onwards
8.6 Expansion into New Markets
8.7 Concluding Thoughts
List of Tables
Table 2.1 Monoclonal Antibody Technology, 2010
Table 2.2 Modes of Action for Therapeutic Monoclonal Antibodies, 2010
Table 2.3 Monoclonal Antibody Therapies Approved by US FDA, 1986-2003
Table 2.4 Monoclonal Antibody Therapies Approved by US FDA, 2003-2010
Table 3.1 Monoclonal Antibody Sales by Therapeutic Area, 2009
Table 3.2 Sales of Leading Therapeutic Monoclonal Antibodies, 2009
Table 3.3 Monoclonal Antibody Sales by Technology Type, 2009
Table 3.4 Sales of Monoclonal Antibodies by Antibody Type, 2009
Table 3.5 Therapeutic Monoclonal Antibody Market: Commercial Drivers & Restraints, 2010-2025
Table 3.6 Total Market, Oncology, Autoimmune Disorder and Other Monoclonal Antibodies: Sales Forecasts, 2010-2015
Table 3.7 Total Market, Oncology, Autoimmune Disorder and Other Monoclonal Antibodies: Sales Forecasts, 2016-2025
Table 3.8 Sales of Leading Anti-Cancer Monoclonal Antibodies, 2009
Table 3.9 Sales by Technology Type: Monoclonal Antibodies for Cancer Treatment, 2009
Table 3.10 Sales by Antibody Type: Monoclonal Antibodies for Cancer Treatment, 2009
Table 3.11 Sales by Marketing Company: Monoclonal Antibodies for Cancer Treatment, 2009
Table 3.12 Monoclonal Antibodies for Cancer Treatment: Commercial Drivers & Restraints, 2010-2025
Table 3.13 Avastin, Herceptin, MabThera/Rituxan, Erbitux & Total Oncology Monoclonal Antibodies: Sales Forecasts, 2010-2015
Table 3.14 Avastin, Herceptin, MabThera/Rituxan, Erbitux & Total Oncology Monoclonal Antibodies: Sales Forecasts, 2016-2025
Table 3.15 Avastin: Commercial Drivers & Restraints, 2010-2025
Table 3.16 Herceptin: Commercial Drivers & Restraints, 2010-2025
Table 3.17 MabThera/Rituxan Total: Oncology and Autoimmune Disorder Sales Forecasts, 2010-2015
Table 3.18 MabThera/Rituxan Total: Oncology and Autoimmune Disorder Sales Forecasts, 2016-2025
Table 3.19 MabThera/Rituxan: Commercial Drivers & Restraints, 2010-2025
Table 3.20 Erbitux: Commercial Drivers & Restraints, 2010-2025
Table 3.21 Sales of Leading Autoimmune Disorder Monoclonal Antibodies, 2009
Table 3.22 Sales by Technology Type: Autoimmune Disorder Monoclonal Antibodies, 2009
Table 3.23 Sales by Antibody Class: Autoimmune Disorder Monoclonal Antibodies, 2009
Table 3.24 Autoimmune Disorder Monoclonal Antibodies: Commercial Drivers & Restraints, 2010-2025
Table 3.25 Remicade, Humira, Tysabri, Cimzia & Total Autoimmune Disorder Monoclonal Antibodies: Sales Forecasts, 2010-2015
Table 3.26 Remicade, Humira, Tysabri, Cimzia & Total Autoimmune Disorder Monoclonal Antibodies: Sales Forecasts, 2016-2025
Table 3.27 Remicade: Commercial Drivers & Restraints, 2010-2025
Table 3.28 Approved Indications for Humira in the US, 2010
Table 3.29 Humira, Commercial Drivers & Restraints, 2010-2025
Table 3.30 Tysabri, Commercial Drivers & Restraints, 2010-2025
Table 3.31 Sales of Other Leading Monoclonal Antibodies (Non-Oncology/Autoimmune Disorders), 2009
Table 3.32 Synagis, Lucentis and Other Non-Oncology/Autoimmune Disorder Monoclonal Antibodies: Sales Forecasts, 2010-2015
Table 3.33 Synagis, Lucentis and Other Non-Oncology/Autoimmune Disorder Monoclonal Antibodies: Sales Forecasts, 2016-2025
Table 3.34 Lucentis: Commercial Drivers & Restraints, 2010-2025
Table 4.1 Leading National Markets for Therapeutic Monoclonal Antibodies, 2009
Table 4.2 Leading National Markets for Therapeutic Monoclonal Antibodies: Sales Forecasts, 2010-2015
Table 4.3 Leading National Markets for Therapeutic Monoclonal Antibodies: Sales Forecasts, 2016-2025
Table 5.1 R&D Pipeline for mAb Cancer Treatments: Additional Indications for Avastin, 2010
Table 5.2 R&D Pipeline for mAb Cancer Treatments: Additional Indications for Approved Drugs (Other than Avastin), 2010
Table 5.3 R&D Pipeline for mAb Cancer Treatments: Selected New Entities in Phase III/Regulatory Submission, 2010
Table 5.4 Autoimmune Disorder R&D Pipeline: Selected New Entities in Phase III, 2010
Table 5.5 Antibody Fragment R&D Pipeline R&D, 2010
Table 5.6 Antibody-Cytotoxic Drug Conjugate R&D Pipeline: Part 1, 2010
Table 5.7 Antibody-Cytotoxic Drug Conjugate R&D Pipeline: Part 2, 2010
Table 6.1 SWOT Analysis of the Monoclonal Antibody Therapeutics Sector, 2010-2025
Table 6.2 Monoclonal Antibody Targets, 2010
Table 6.3 Expected Patent Expiries for Therapeutic Monoclonal Antibodies
Table 6.4 Biosimilar Monoclonal Antibodies in Development, 2010
List of Figures
Figure 2.1 Antibody Structure
Figure 3.1 Therapeutic Monoclonal Antibodies: Market Shares by Therapeutic Area, 2009
Figure 3.2 Leading Therapeutic Monoclonal Antibodies: Market Shares, 2009
Figure 3.3 Therapeutic Monoclonal Antibodies: Market Shares by Technology Type, 2009
Figure 3.4 Therapeutic Monoclonal Antibodies: Market Shares by Antibody Class, 2009
Figure 3.5 Therapeutic Monoclonal Antibodies: Overall World Sales Forecast, 2010-2025
Figure 3.6 Oncology, Autoimmune Disorder and Other Monoclonal Antibodies: Sales Forecasts, 2010-2025
Figure 3.7 Oncology, Autoimmune Disorder and Other Monoclonal Antibodies: Market Shares, 2010-2025
Figure 3.8 Monoclonal Antibodies for Cancer Treatment: Market Shares, 2009
Figure 3.9 Monoclonal Antibodies for Cancer Treatment: Market Shares by Technology Type, 2009
Figure 3.10 Monoclonal Antibodies for Cancer Treatment: Market Shares by Antibody Class, 2009
Figure 3.11 Monoclonal Antibodies for Cancer Treatment: Market Shares by Company, 2009
Figure 3.12 Monoclonal Antibodies for Cancer Treatment: Sales Forecast, 2010-2025
Figure 3.13 Monoclonal Antibodies for Cancer Treatment: Sales Breakdowns by Brand, 2009, 2015, 2020 and 2025
Figure 3.14 Avastin: Sales Forecast, 2010-2025
Figure 3.15 Herceptin: Sales Forecast, 2010-2025
Figure 3.16 MabThera/Rituxan: Total, Oncology and Autoimmune Disorder Sales Forecasts, 2010-2025
Figure 3.17 Erbitux: Sales Forecast, 2010-2025
Figure 3.18 Autoimmune Disorder Monoclonal Antibodies: Market Shares, 2009
Figure 3.19 Autoimmune Disorder Monoclonal Antibodies: Market Shares by Technology Type, 2009
Figure 3.20 Autoimmune Disorder Monoclonal Antibodies: Market Shares by Antibody Class, 2009
Figure 3.21 Autoimmune Disorder Monoclonal Antibodies: Sales Forecast, 2010-2025
Figure 3.22 Autoimmune Disorder Monoclonal Antibodies: Sales Breakdowns by Brand, 2009, 2015, 2020 and 2025
Figure 3.23 Remicade: Sales Forecast, 2010-2025
Figure 3.24 Humira: Sales Forecast, 2010-2025
Figure 3.25 Xolair: Sales Forecast, 2010-2025
Figure 3.26 Total Non-Oncology/Autoimmune Disorder Monoclonal Antibodies: Sales Forecast, 2010-2025
Figure 3.27 Synagis: Sales Forecast, 2010-2025
Figure 3.28 Lucentis: Sales Forecast, 2010-2025
Figure 4.1 Leading National Markets for Therapeutic Monoclonal Antibodies: Market Shares, 2009
Figure 4.2 Leading National Markets for Therapeutic Monoclonal Antibodies: Market Shares, 2015
Figure 4.3 Leading National Markets for Therapeutic Monoclonal Antibodies: Market Shares, 2025
Companies Listed
Abbott Laboratories
Abgenix (acquired by Amgen, 2006)
Ablynx
Actinium Pharmaceuticals
Affimed Therapeutics
Alcon (Nestle)
Alexion Pharmaceuticals
Alnylam
Amgen
Arana Therapeutics
AstraZeneca
Bayer HealthCare
Biocon
Biogen (merged with IDEC in 2003 to form Biogen Idec)
Biogen Idec
BioTech Pharma
Biotest
Boehringer Ingelheim
Bradmer Pharmaceuticals
Bristol-Myers Squibb (BMS)
Cambridge Antibody Technology (CAT) (acquired by AstraZeneca)
Cell Therapeutics
Celltech (acquired by UCB, 2004)
Center of Molecular Immunology [Cuba]
Centocor Ortho Biotech (acquired by Johnson & Johnson, 1999)
Cephalon
Ception Therapeutics
Chugai Pharmaceutical Co
Committee for Medicinal Products for Human Use (CHMP) [EU]
Corixa (acquired by GSK, 2005)
Daiichi-Sankyo
Dainippon Sumitomo
Domantis (acquired by GSK, 2007)
Dr. Reddy's Laboratories
Eisai Pharmaceuticals
Elan Corporation
Eli Lilly and Company
ESBATech
ESTEVE
Eurofarma Laboratorios
European Medicines Agency (EMA, EMEA)
Facet Biotech
Food and Drug Administration (FDA) [US]
Fresenius
Genentech (acquired by Roche in 2009)
Genmab
Genzyme
GlaxoSmithKline (GSK)
GTC Biotherapeutics
Health Canada
Human Genome Sciences
IDEC (merged with Biogen in 2003 to form Biogen Idec)
Ilex Oncology (acquired by Genzyme, 2004)
ImClone (acquired by Eli Lilly, November 2008)
ImmunoGen
Immunomedics
Implicit Bioscience
Johnson & Johnson
Kyowa Hakko Kirin
Laboratorio Elea
LFB Biotechnologies
Ludwig Institute for Cancer Research
MacroGenics
Medarex
MedImmune (acquired by AstraZeneca, 2007)
Menarini
Merck & Co.
Merck KGaA
Merck Serono
Micromet
Millennium (acquired by Takeda, 2008)
Ministry of Health, Labour and Welfare (MHLW) [Japan]
Mitsubishi Tanabe Pharma Corporation
Morphotek (acquired by Eisai, 2007)
National Cancer Institute (NCI, part of NIH) [US]
National Eye Institute (NEI, part of NIH) [US]
National Institutes of Health (NIH) [US]
NeuTec (acquired by Novartis, 2006)
Novartis
Nycomed Pharma
Oncoscience
Onyx Pharmaceuticals
Osaka University
Otsuka Pharmaceutical Co
PDL BioPharma
Peregrine Pharmaceuticals
Pfizer
Pierre Fabre
Progenics Pharmaceuticals
Ranbaxy Laboratories
Rinat (acquired by Pfizer, 2006)
Roche
Roche Group (Roche, Genentech & Chugai)
Sanofi-Aventis
Schering-Plough
Seattle Therapeutics
Shanghai Medipharm Biotech (Medipharm)
Shantha Biotechnics
Southampton General Hospital [UK]
Spectrum Pharmaceuticals
State Food and Drug Administration (SFDA) [China]
Takeda Pharmaceutical Company
Tanox (acquired by Genentech in 2007)
Tolerx
TRION Pharma
Tufts University
UCB
University of Massachusetts Medical School
Viventia Biotechnologies
Wilex
Wyeth (now part of Pfizer)
Xoma
YM Biosciences
Zenotech Laboratories
Zenyaku Kogyo Co
To order this report:
Biological Therapy Industry: Therapeutic Monoclonal Antibodies: World Market 2010-2025
Biological Therapy Business News
Check our Company Profile, SWOT and Revenue Analysis!
|
Contact Nicolas Bombourg |
|
|
Reportlinker |
|
|
Email: [email protected] |
|
|
US: (805)652-2626 |
|
|
Intl: +1 805-652-2626 |
|
SOURCE Reportlinker